Reuben N Robbins1, Henry Brown2, Andries Ehlers2, John A Joska3, Kevin G F Thomas4, Rhonda Burgess5, Desiree Byrd5, Susan Morgello5. 1. HIV Center for Clinical and Behavioral Studies, Columbia University and the New York State Psychiatric Center, New York, New York. 2. Envisage IT, Cape Town, South Africa. 3. The Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. 4. ASCENT Laboratory, Department of Psychology, University of Cape Town, Cape Town, South Africa. 5. The Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
BACKGROUND: Neurocognitive Impairment (NCI) is one of the most common complications of HIV-infection, and has serious medical and functional consequences. However, screening for it is not routine and NCI often goes undiagnosed. Screening for NCI in HIV disease faces numerous challenges, such as limited screening tests, the need for specialized equipment and apparatuses, and highly trained personnel to administer, score and interpret screening tests. To address these challenges, we developed a novel smartphone-based screening tool, NeuroScreen, to detect HIV-related NCI that includes an easy-to-use graphical user interface with ten highly automated neuropsychological tests. AIMS: To examine NeuroScreen's: 1) acceptability among patients and different potential users; 2) test construct and criterion validity; and 3) sensitivity and specificity to detect NCI. METHODS: Fifty HIV+ individuals were administered a gold-standard neuropsychological test battery, designed to detect HIV-related NCI, and NeuroScreen. HIV+ test participants and eight potential provider-users of NeuroScreen were asked about its acceptability. RESULTS: There was a high level of acceptability of NeuroScreen by patients and potential provider-users. Moderate to high correlations between individual NeuroScreen tests and paper-and-pencil tests assessing the same cognitive domains were observed. NeuroScreen also demonstrated high sensitivity to detect NCI. CONCLUSION: NeuroScreen, a highly automated, easy-to-use smartphone-based screening test to detect NCI among HIV patients and usable by a range of healthcare personnel could help make routine screening for HIV-related NCI feasible. While NeuroScreen demonstrated robust psychometric properties and acceptability, further testing with larger and less neurocognitively impaired samples is warranted.
BACKGROUND:Neurocognitive Impairment (NCI) is one of the most common complications of HIV-infection, and has serious medical and functional consequences. However, screening for it is not routine and NCI often goes undiagnosed. Screening for NCI in HIV disease faces numerous challenges, such as limited screening tests, the need for specialized equipment and apparatuses, and highly trained personnel to administer, score and interpret screening tests. To address these challenges, we developed a novel smartphone-based screening tool, NeuroScreen, to detect HIV-related NCI that includes an easy-to-use graphical user interface with ten highly automated neuropsychological tests. AIMS: To examine NeuroScreen's: 1) acceptability among patients and different potential users; 2) test construct and criterion validity; and 3) sensitivity and specificity to detect NCI. METHODS: Fifty HIV+ individuals were administered a gold-standard neuropsychological test battery, designed to detect HIV-related NCI, and NeuroScreen. HIV+ test participants and eight potential provider-users of NeuroScreen were asked about its acceptability. RESULTS: There was a high level of acceptability of NeuroScreen by patients and potential provider-users. Moderate to high correlations between individual NeuroScreen tests and paper-and-pencil tests assessing the same cognitive domains were observed. NeuroScreen also demonstrated high sensitivity to detect NCI. CONCLUSION: NeuroScreen, a highly automated, easy-to-use smartphone-based screening test to detect NCI among HIV patients and usable by a range of healthcare personnel could help make routine screening for HIV-related NCI feasible. While NeuroScreen demonstrated robust psychometric properties and acceptability, further testing with larger and less neurocognitively impaired samples is warranted.
Entities:
Keywords:
HIV; application; neurocognitive; smartphone; test
Authors: Catherine L Carey; Steven Paul Woods; Julie D Rippeth; Raul Gonzalez; David J Moore; Thomas D Marcotte; Igor Grant; Robert K Heaton Journal: Clin Neuropsychol Date: 2004-05 Impact factor: 3.535
Authors: E J Wright; B Grund; K Robertson; B J Brew; M Roediger; M P Bain; F Drummond; M J Vjecha; J Hoy; C Miller; A C Penalva de Oliveira; W Pumpradit; J C Shlay; W El-Sadr; R W Price Journal: Neurology Date: 2010-08-11 Impact factor: 9.910
Authors: Ned C Sacktor; Matthew Wong; Noeline Nakasujja; Richard L Skolasky; Ola A Selnes; Seggane Musisi; Kevin Robertson; Justin C McArthur; Allan Ronald; Elly Katabira Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: Charles H Hinkin; David J Hardy; Karen I Mason; Steven A Castellon; Ramani S Durvasula; Mona N Lam; Marta Stefaniak Journal: AIDS Date: 2004-01-01 Impact factor: 4.177
Authors: Kara Anne Bottiggi; Jason J Chang; Frederick A Schmitt; Malcolm J Avison; Yunanan Mootoor; Avindra Nath; Joseph R Berger Journal: J Neurol Sci Date: 2007-05-04 Impact factor: 3.181
Authors: Mark L Ettenhofer; Charles H Hinkin; Steven A Castellon; Ramani Durvasula; Jodi Ullman; Mona Lam; Hector Myers; Matthew J Wright; Jessica Foley Journal: Am J Geriatr Psychiatry Date: 2009-04 Impact factor: 4.105
Authors: J A Joska; J Witten; K G Thomas; C Robertson; M Casson-Crook; H Roosa; J Creighton; J Lyons; J McArthur; N C Sacktor Journal: AIDS Behav Date: 2016-08
Authors: Emmanuel K Mwesiga; Dickens Akena; Nastassja Koen; Richard Senono; Ekwaro A Obuku; Joy Louise Gumikiriza; Reuben N Robbins; Noeline Nakasujja; Dan J Stein Journal: Schizophr Res Cogn Date: 2020-08-24
Authors: R N Robbins; L Kluisza; J Liu; A F Santoro; J Raymond; N Ngyuen; S Espinel; E Siegel; C Dolezal; A Wiznia; E J Abrams; C A Mellins Journal: AIDS Behav Date: 2020-11-12
Authors: Reuben N Robbins; Hetta Gouse; Henry G Brown; Andries Ehlers; Travis M Scott; Cheng-Shiun Leu; Robert H Remien; Claude A Mellins; John A Joska Journal: JMIR Mhealth Uhealth Date: 2018-01-05 Impact factor: 4.773